R-2-hydroxyglutarate (R-2HG), originally reported as an oncometabolite highly produced by mutant isocitrate dehydrogenase 1/2 (IDH1/2) enzymes, suppressed leukemia cell proliferation/viability and promoted cell-cycle arrest and apoptosis by inhibiting FTO demethylase activity and manipulating the expression levels of CCAAT/enhancer-binding protein alpha (CEBPA) and MYC (Figs. 3a, 6b) [57]. The gene discussed is IDH1; the disease is leukemia.